Compass Therapeutics, Inc.
NASDAQ:CMPX
1.8 (USD) • At close November 8, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 1.89 | 1.904 | 1.624 | 2.404 | 2.12 | 1.921 |
| Gross Profit
| -1.89 | -1.904 | -1.624 | -2.404 | -2.12 | -1.921 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 37.421 | 29.997 | 20.337 | 14.904 | 22.449 | 27.095 |
| General & Administrative Expenses
| 12.243 | 11.658 | 10.927 | 12.908 | 11.603 | 11.217 |
| Selling & Marketing Expenses
| 11.04 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 11.052 | 11.658 | 10.927 | 12.908 | 11.603 | 11.217 |
| Other Expenses
| 0 | 0 | 50.618 | 0 | 0 | 0 |
| Operating Expenses
| 48.473 | 41.655 | 31.264 | 27.812 | 34.052 | 38.312 |
| Operating Income
| -50.363 | -41.655 | -81.882 | -27.812 | -34.052 | -38.312 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 7.869 | 2.43 | -0.299 | -1.656 | -0.601 | 0.233 |
| Income Before Tax
| -42.494 | -39.225 | -82.181 | -29.468 | -34.653 | -38.183 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | -2.43 | 0.37 | 0.032 | 0.091 | 0.103 |
| Net Income
| -42.494 | -36.795 | -82.551 | -29.5 | -34.744 | -38.286 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.33 | -0.35 | -1.31 | -0.96 | -0.67 | -0.73 |
| EPS Diluted
| -0.33 | -0.35 | -1.31 | -0.96 | -0.67 | -0.73 |
| EBITDA
| -48.473 | -37.391 | -29.611 | -25.32 | -31.189 | -35.728 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |